Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NIH trial with omega-3

This article was originally published in The Tan Sheet

Executive Summary

The National Institute on Aging announces May 10 it will conduct a clinical trial evaluating whether omega-3 fatty acids slow the progression of cognitive and functional decline in people with Alzheimer's disease. The trial will take place at 51 sites and will include 400 participants, who will take either 2 g daily of Martek Biosciences donated life'sDHA or placebo. The National Institutes of Health agency says the study is one of a number it will undertake in the next few years to test compounds that might help prevent or delay Alzheimer's. A study published in the November Archives of Neurology found a higher level of DHA reduces the risk of developing all-cause dementia (1"The Tan Sheet" Nov. 20, 2006, p. 6)...

You may also be interested in...



Martek’s DHA Pricing Stand Based On Long-Term Growth, Fish Oil Competition

Martek Biosciences has largely avoided raising prices on its nutritional oil products despite rising material costs because the firm does not want to surrender its competitive advantage in the infant formula and other markets, according to CEO Steve Durbin

Higher DHA Intake Associated With Reduced Risk Of Dementia – JAMA Study

A higher level of DHA in the blood is associated with a 47% reduction in the risk of developing all-cause dementia, a study in the November Archives of Neurology finds

Two Studies Support Short Dual Antiplatelet Therapy With Abbott’s Xience DES

Results from two trials confirm patients at high risk of bleeding treated with Abbott’s Xience stent can be safely treated with short regimens of dual antiplatelet therapy.

Topics

UsernamePublicRestriction

Register

GB150348

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel